Squamous Cell Carcinoma Clinical Trials

None

None

None

None

Substudy: Understanding COVID-19 vaccine responses in the setting of immunotherapy

Anti-PD-1 antibody infusion is now increasingly being tested for other cancers as well, with relatively recent FDA-approval for use in metastatic non-small cell lung cancer, renal cell carcinoma, and metastatic or recurrent head and neck squamous cell carcinoma. This study is designed to better understand antibody responses in the setting …

Trial of ASP-1929 Photoimmunotherapy Versus Physician's Choice Standard of Care for the Treatment of Locoregional Recurrent Head and Neck Squamous Cell Carcinoma

This is a Phase 3, randomized, double-arm, open-label trial of ASP-1929 photoimmunotherapy (ASP-1929 PIT) versus physician's choice standard of care (SOC) for the treatment of locoregional, recurrent head and neck squamous cell carcinoma (HNSCC) in patients who have failed or progressed on or after at least two lines of therapy, …

Trial of INO-5401 and INO-9012 Delivered by Electroporation (EP) in Combination with REGN2810 in Subjects with Newly-Diagnosed Glioblastoma (GBM)

Cemiplimab is approved by the U.S Food and Drug Administration (FDA) for the treatment of metastatic cutaneous squamous cell carcinoma (CSCC), but is not approved by any regulatory agency for the treatment of any other cancer or disease. Cemiplimab investigational product is currently being studied in patients with cancer in other …